Immune-Driven Precision Medicine
Various
DiscoveryActive
Key Facts
About IMU Biosciences
IMU Biosciences is an early-stage biotech leveraging AI and multi-omics to map the immune system at unprecedented scale and resolution. Its proprietary platform, built on research from King's College London and the Francis Crick Institute, analyzes vast immune datasets to discover novel signatures for drug development and precision medicine applications. The company is positioned as a platform and discovery partner for pharmaceutical companies, aiming to increase R&D success and enable immune-driven diagnostics and therapies.
View full company profileTherapeutic Areas
Other Various Drugs
| Drug | Company | Phase |
|---|---|---|
| New Generic Approvals | China SXT Pharmaceuticals | Application Submitted / BE Stage |
| New Dosage Form Development | Universe Pharmaceuticals | Development |
| New TCM Formula Registration | Universe Pharmaceuticals | Development |
| CBD/THC Oil Formulation | Avecho Biotechnology | Preclinical |
| Bag APIs | ChemWerth | Approved |
| Oral APIs | ChemWerth | Approved |
| Companion Diagnostics Development | Kiffik Biomedical | Pre-clinical |
| Portfolio of Complex Generics & 505(b)(2) Products | Alvogen | Approved/Commercial |
| Portfolio of 40+ products | Praxgen Pharmaceuticals | Development |
| Drug Repositioning Service | Biovista | Service |
| Custom Control Development | Anchor Molecular | Development/Commercial |
| Portfolio from Steriscience Partnership | Armas Pharmaceuticals | ANDA Development/Filing |